Erazaban® [Docosanol]
1544 Items
2019-09-19
- done All payments are SSL encrypted
- done Full Refund if you haven't received your order
- done International shipping to the USA, UK and Europe
Clinical Pharmacology
Pharmacotherapeutic group: antiviral agent
ATX Code: D06BB11
pharmachologic effect
Pharmacodynamics
Docosanol is an antiviral agent. In vitro studies have shown that docosanol affects the fusion of the virus with the plasma membrane, which inhibits the penetration of the virus into the cell and its subsequent replication. This mechanism of action makes it unlikely that the Herpes simplex strains resistant to the antiviral effects of docosanol will appear and also protects against the entry of virus strains into healthy cells. In vitro studies have shown that cells exposed to docosanol are resistant to infections caused by lipid-membrane viruses, such as the first type of Herpes simplex virus.
Pharmacokinetics
When applied externally, the drug is practically not subjected to systemic absorption.
Docosanol is metabolized intracellularly to docosanoic acid (the main metabolite). Docosanol and its metabolite are endogenous components of human cell membranes.
When applying the cream on intact (healthy) skin: the absorption is minimal, not detected in the blood. When applied to the affected skin: moderate absorption. Excreted by the kidneys.
Indications
Skin infections caused by Herpes simplex type 1 virus (including lip herpes) in immunocompetent patients.
Composition
1 g of cream contains:
Active substances: docosanol 100 mg
Excipients: sucrose 50 mg, mineral oil 80 mg, propylene glycol 50 mg, benzyl alcohol 27 mg, water 693 mg.
No customer reviews for the moment.
Dosage and Administration
Topically. The drug is recommended to be applied to adults and children over 12 years of age 5 times a day (approximately every 3 hours) as soon as possible after the onset of infection, applied in a thin layer on the affected skin areas. The average recovery time is 4 days.
The cream is applied either with a cotton swab or with clean hands to avoid further infection of the affected areas.
The effectiveness of therapy administered with this drug depends on the time of initiation of therapy: the sooner therapy is started from the onset of symptoms, the higher the efficiency. In the case of the start of treatment of a relapsing infection during the prodromal phase or at the very beginning, the drug Erazaban prevents the appearance of bubble eruptions and the formation of crusts.
It is necessary to conduct a full course of therapy for 5 days, in order to achieve the greatest effect from the therapy, even if the signs of infection disappear after 1-2 days of treatment. In the absence of healing, treatment can be continued for up to 10 days.
Dose adjustment in elderly patients and in patients with impaired renal function is not required.
If the symptoms persist for more than 10 days, you should consult a doctor.
Adverse reactions
Headache; on the application sites: dry skin, skin itching, rash, short-term redness, soreness, peeling, burning or tingling.
These side effects, as a rule, do not require discontinuation of the drug.
There are isolated reports of cases of angioedema during external use of the drug.
If any of the side effects indicated in the instruction are aggravated, or you have noticed any other side effects not indicated in the instruction, inform your doctor.
Contraindications
Hypersensitivity to docosanol or any other component of the drug, age up to 12 years (no experience with the application).
Drug interactions
When applied externally, no interaction with other drugs was detected.
Pregnancy and Lactation
Preclinical studies in animals have not revealed teratogenic and embryotoxic effects on the fetus.
Before using the drug Arazaban during pregnancy or during breastfeeding, you should consult a doctor.
Special instructions
The drug Arazaban is intended for external use only!
Avoid contact with eyes and do not apply to the skin near the eyes. To achieve the maximum therapeutic effect, it is necessary to use the drug at the first signs of the disease (burning, itching, tingling, feeling of tension and redness).
The drug contains propylene glycol and may cause skin irritation. The cream should not be used in immunocompromised patients.
Influence on ability to steer vehicles, mechanisms
Does not affect.
Overdosage
No cases of drug overdose have been reported.
- Brand name: Erazaban
- Active ingredient: Docosanol
- Dosage form: Cream for external use.
- Manufacturer: Oberon
Studies and clinical trials of Docosanol (Click to expand)
- ChemInform Abstract: Synthesis of 1-Docosanol.
- Topical application of docosanol- or stearic acid-containing creams reduces severity of phenol burn wounds in mice
- The infrared spectra and polymorphism of long chain esters: IV. Some esters from tetradecanol, hexadecanol, octadecanol, eicosanol, docosanol and dodecanoic, tetradecanoic, hexadecanoic, octadecanoic and eicosanoic acid
- n-docosanol prevents vaginal transmission of SIVmac251 in rhesus macaques
- Comparison of n-docosanol cream (LIDAKOL™) with acyclovir ointment (Zovirax™) in the inhibition of cutaneous herpes simplex virus (HSV) infections in two guinea pig model systems: J.F. Marcelletti, R.R. McFadden, M.H. Khalil, L.E. Pope, R.C. Davis, L.R. Katz, and D.H. Katz. LIDAK Pharmaceuticals, 11077 N. Torrey Pines Road, La Jolla, CA 92037
- Inhibition of corrosion by poly(N-hexadecylaniline)/docosanol mixed Langmuir–Blodgett films on copper in sea water
- Synergistic inhibition of herpesvirus replication by docosanol and antiviral nucleoside analogs
- The anti-herpes simplex virus (HSV) activity of n-docosanol includes inhibition of the viral entry process: *L.E. Pope, *J.F. Marcelletti, **M.L. Parish, **P.G. Spear and *D.H. Katz. *LIDAK Pharmaceuticals, La Jolla, CA, USA and **Northwestern University Medical School, Chicago, IL, USA
- The anti-herpes simplex virus activity of n-docosanol includes inhibition of the viral entry process
- Clinical efficacy of topical docosanol 10% cream for herpes simplex labialis: A multicenter, randomized, placebo-controlled trial
- N-docosanol (Abreva) for herpes labialis: Problems and questions
- Efficacy of docosanol
- Heat Capacities and Derived Thermodynamic Functions of 1-Octadecanol, 1-Nonadecanol, 1-Eicosanol, and 1-Docosanol between 10 K and 370 K
- Inhibition of Copper Corrosion in Aqueous Sodium Chloride Solution by N-Octadecylbenzidine/1-Docosanol Mixed Langmuir-Blodgett Films
- Docosanol 10% cream [Avanir Pharmaceuticals] approved in Korea
- Avanir Pharmaceuticals' docosanol 10% cream approved in Israel
- Docosanol: a topical antiviral for herpes labialis
- Measurement of .gamma..infin. using gas-liquid chromatography. 1. Results for the stationary phases n-octacosane, 1-docosanol, 10-nonadecanone, and 1-eicosene
- The Antiviral Drug Docosanol as a Treatment for Kaposi's Sarcoma Lesions in HIV Type 1-Infected Patients: A Pilot Clinical Study
8 other products in the same category:
arrow_upward